Successful use of recombinant activated coagulation factor VII in a patient with massive hemoptysis from a penetrating thoracic injury.

Abstract

Acute massive hemoptysis is a rare complication of pulmonary injury and contusion, and it is particularly difficult to manage in the nontertiary care setting. Recombinant activated coagulation factor VII (rFVIIa) is a prothrombotic drug that is increasingly being used to treat coagulopathy in massively exsanguinating trauma patients. We report a case in which recombinant activated coagulation factor VII successfully controlled massive hemoptysis and improved ventilation from a severe pulmonary contusion in a noncoagulopathic patient who suffered a penetrating thoracic injury in a military setting in Afghanistan.

• Authors: Homer C N Tien, Michael R C Gough, Robert Farrell, John Macdonald
• Journal: The Annals of thoracic surgery (Ann Thorac Surg) Vol. 84 Issue 4 Pg. 1373-4 (Oct 2007) ISSN: 1552-6259 [Electronic] Netherlands
• PMID: 17889002 (Publication Type: Case Reports, Journal Article)

Chemical References

• Hemostatics
• Recombinant Proteins
• recombinant FVIIa
• Factor VIIa

Topics

• Adult
• Combined Modality Therapy
• Dose-Response Relationship, Drug
• Factor VIIa (administration & dosage)
• Follow-Up Studies
• Hemoptysis (etiology, therapy)
• Hemostatics (administration & dosage)
• Humans
• Lung Injury
• Male
• Recombinant Proteins (administration & dosage)
• Risk Assessment
• Severity of Illness Index
• Thoracic Injuries (complications, diagnosis)
• Thoracotomy (methods)
• Treatment Outcome
• Wounds, Gunshot (complications, diagnosis)